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The circulating FGFs are a new group of proteins believed to function as classic hormones.With emphasis on
human metabolism, we critically review current data, and propose that—although a number of questions
remain—circulating FGF23 is pivotal in the control of phosphate and vitamin D metabolism, and may have
additional systemic effects, particularly in chronic kidney disease; that FGF19 signaling is important for
the regulation of bile acid metabolism, whereas its physiological role in promoting glucose and lipid metab-
olism is less well understood; and that the physiological role of circulating FGF21 in metabolic homeostasis
warrants further investigation.Introduction
The fibroblast growth factors (FGFs) represent a large gene
family of proteins involved in cell growth and differentiation,
embryonic development, angiogenesis, and wound healing
(Beenken and Mohammadi, 2009). The human FGF gene family
is comprised of 22 members (FGFs1–23), with FGF15 being
the mouse ortholog of human FGF19. The ‘‘classic’’ FGFs are
secreted heparin-binding proteins that interact with cell-
surface-associated FGF receptors (FGFRs) to elicit signal trans-
duction. FGF19, FGF21, and FGF23 are members of a gene
subfamily with unique properties due to their structural resem-
blance and presumed ‘‘hormone-like’’ actions (Itoh, 2010;
Long and Kharitonenkov, 2011). Usually referred to as
‘‘endocrine’’ FGFs, they have been identified in vertebrates but
not in invertebrates. Like all other FGFs, the FGF19 subfamily
members signal through one or several of the FGFRs, but their
receptor activation mechanisms appear unique. Lacking the
heparin-binding domains present in the other FGFs, they require
specific membrane-bound cofactors, a-Klotho and b-Klotho, for
FGFR binding and activation (Kurosu and Kuro, 2009). The
absence of heparin-binding domains also prevents binding to
heparin sulfate proteoglycans on extracellular membranes,
resulting in the presence of significant concentrations of these
FGFs in circulating blood. According to current view, the indi-
vidual ‘‘endocrine’’ FGFs are thought to act as ‘‘hormone-like’’
circulating regulators of important metabolic pathways: FGF19
controlling the enterohepatic bile acid/cholesterol system,
FGF21 modulating fatty acid/glucose metabolism, and FGF23
regulating phosphate/vitamin D metabolism (Beenken and
Mohammadi, 2009; Ge et al., 2012; Itoh, 2010; Kir et al.,
2011b; Kurosu and Kuro, 2009; Long and Kharitonenkov, 2011;
Wolf, 2012). Highly simplified outlines of these three pathways
are presented in Figure 1.
These conceptual models generally build on animal experi-
ments, mainly performed in mice, utilizing knockout and trans-
genic technologies and treatments with recombinant proteins.
The rapid development of methods quantitating serum levelsof FGFs in humans has led to the accumulation of large amounts
of information from clinical and experimental studies in humans
during the last few years. Variations between groups of in-
dividuals and effects of dietary, hormonal, and pharmacological
interventions have been studied and are generally interpreted in
relation to the current ‘‘endocrine’’ models emanating from
animal experiments.
To fulfill the criteria outlined for a ‘‘hormone,’’ a circulating
protein should be ‘‘a molecule secreted in a regulated fashion
from one organ and acting on another’’ (Funder, 2011). In this
review, we discuss critically whether circulating FGFs 19, 21,
and 23 fulfil these general criteria. Among aspects to be consid-
ered for each of them are the following: Where is its site of
production? How is it transported to its target organ? Which
structures does it interact with? What is the range of concentra-
tions that can elicit a response? What is the range of concentra-
tions present in the circulation? Which physiological changes
influence the circulating levels of the active substance? After
a brief discussion of general aspects of their properties, we will
consider each one of the circulating FGFs in more detail.
General Aspects
Production of Circulating FGFs
While there is an extensive expression catalog of FGFs and their
receptors and coreceptors for themouse (Fon Tacer et al., 2010),
the information on FGF gene expression in human tissues is
limited. On the other hand, the information on levels of circulating
FGFs and their variation in humans is much more extensive. In
fact, while circulating FGF21 and FGF23 have been demon-
strated in several animal species (Yamazaki et al., 2002), the
presence of FGF15 in rodent blood plasma remains unconfirmed
(Montagnani et al., 2011). Furthermore, the homology between
mouse FGF15 and human FGF19 is 40%. In adult mice,
FGF15mRNA ismainly expressed in the ileum, where its produc-
tion is under control of the bile acid receptor FXR. FGF21 mRNA
is abundant in pancreas and testis, and also in the liver where it is
induced by fasting and ketogenic diets under control of theCell Metabolism 16, December 5, 2012 ª2012 Elsevier Inc. 693
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Figure 1. Highly Simplified Scheme of
Putative and Possible Regulatory Pathways
for the ‘‘Endocrine’’ FGFs 19, 21, and 23
FGF23 (indigo) is formed in bone induced by
vitamin D (1,25D) that also promotes the intestinal
uptake of calcium and phosphorous (Ca2+, Pi).
FGF23 stimulates renal excretion of Pi while it
reduces vitamin D by both increasing its degra-
dation and reducing its formation. FGF23 also
reduces parathyroid hormone (PTH) secretion
from the parathyroid glands. The reduced PTH
tonus reduces FGF23 formation in bone. FGF19
(red) is presumably released from the small intes-
tine when bile acids traversing the enterocytes
activate the intestinal bile acid receptor FXR.
FGF19 signals to the liver, contributing to the
suppression of bile acid synthesis. After a meal,
postprandial FGF19 may induce gallbladder filling.
Postprandial FGF19may stimulate hepatic buildup
of glycogen along with reduced glucose and
triglycerides in plasma. (In mice and rats, FGF15 is
considered to exert the corresponding effects; its
presence in blood has not yet been shown.) FGF21
(blue) is produced in the liver, white adipose tissue
(WAT), and pancreas and presumably exerts local
metabolic effects in those organs. When given/
produced (infusion/transgenic) at high doses, the
metabolic rate is stimulated and glucose and
triglycerides in plasma are reduced. Some meta-
bolic effects of FGF21, and possibly also of
FGF19, may be exerted at the ventrolateral hypo-
thalamic level. (For reviews, see Beenken and
Mohammadi, 2009; Ge et al., 2012; Itoh, 2010; Kir
et al., 2011b; Kurosu and Kuro, 2009; Long and
Kharitonenkov, 2011; Wolf, 2012.)
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a bone-derived protein mainly produced by osteocytes and
osteoblasts; it is expressed at low levels in spleen, thymus,
and specific parts of the brain. FGF23 is under control of the
vitamin D receptor (VDR), again showing that transcriptional
regulation of the circulating FGFs is at least partly controlled
by nuclear receptors (Figure 1; Beenken and Mohammadi,
2009; Ge et al., 2012; Itoh, 2010; Kir et al., 2011b; Kurosu and
Kuro, 2009; Long and Kharitonenkov, 2011; Wolf, 2012).
Measurements of Circulating FGFs
Currently available techniques for measuring serum levels of
FGF19 and FGF21 use immunological methods, generally RIA-694 Cell Metabolism 16, December 5, 2012 ª2012 Elsevier Inc.or ELISA-based assays. These are gener-
ally unable to discriminate between bio-
active and inactive or between agonistic
and antagonistic forms of the proteins.
For FGF23, an assay that detects both
human and rodent proteins and only
detects the bioactive FGF23 protein was
developed early (Yamazaki et al., 2002),
but there are also several commercially
available assays for the human, mouse,
and rat proteins. The reported serum
levels of FGFs in healthy subjects after
overnight fast show a skewed distribution
and large interindividual variation, with
median levels of FGF21 > FGF19 >
FGF23 (Figure 2).The kinetics of circulating FGFs have not been investigated in
detail, and there is limited information regarding possible binder
proteins. Secreted intact FGF23 appears stable in the circulation
until it is degraded in the kidney. Based on findings after removal
of FGF23-producing tumors, its circulatory half-life is estimated
to be 45–60 min (Khosravi et al., 2007). The half-life of injected
human FGF21 is 30 min in monkeys (Kharitonenkov et al.,
2007). Based on their molecular size of 32–36 kDa (depending
on glycosylation), the circulating FGFs should pass the glomer-
ular barrier, resulting in renal elimination. In healthy subjects,
serum levels of FGF23 correlate inversely with glomerular filtra-
tion rate and rise in parallel with declining renal function (Larsson
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Figure 2. FGF19, FGF21, and FGF23 in Plasma fromNormal Subjects
after Overnight Fasting
FGF19 and FGF21 were assayed in samples from 76 healthy individuals (39
women and 37men, 20–80 years old) as described (Galman et al., 2008, 2011).
FGF23 measurements are based upon a random selection of 100 individuals
from a community-based cohort of elderly individuals (PIVUS; Prospective
Investigation of the Vasculature in Uppsala Seniors; Mirza et al., 2009).
Horizontal bars represent means.
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and FGF21 in patients with renal insufficiency (Han et al., 2010;
Lin et al., 2011; Reiche et al., 2010).
As mentioned, there has been a rapid accumulation of reports
describing levels of circulating FGFs in a broad set of clinical
conditions. The influence of factors such as age and gender on
levels of circulating FGFs seems to be of limited importance. A
diurnal variation has been demonstrated for FGF19, with clear
postprandial peaks that are abolished when food is omitted
(Lundasen et al., 2006). Circulating FGF21 appears to be higher
in the morning and lower in the late afternoon, but this is not an
obligate finding (Galman et al., 2008; Lee et al., 2012; Yu et al.,
2011). For FGF23, the active peptide seems to increase during
daytime (Vervloet et al., 2011). These findings stress the impor-
tance of standardizing sampling procedures. Circulating levelsof FGFs 19 and 21 measured after overnight fasting seem to
be relatively stable in an individual over time (Angelin et al., 2010).
Compared to FGF23, there is a wide interindividual variation of
fasting levels for FGF19 and, in particular, FGF21 (Figure 2). It is
unusual for highly bioactive substances to have wide normal
ranges in healthy subjects, and it may be speculated that this
implies that the absolute level is not critical for homeostasis.
Genetic variation in protein synthesis, processing, and elimina-
tion may be important for this variation, and this needs further
exploration.
Expression of FGF Receptors and Their Coreceptors
All members of the FGF19 family bind to at least one of the four
FGFRs, 1–4, where the FGFRs 1–3 each have at least two splice
variants (Ornitz et al., 1996). Also the information about FGFR
tissue distribution is largely derived from mice and indicates
a ubiquitous expression of all FGFRs (Fon Tacer et al., 2010).
In contrast to the ‘‘canonical’’ FGFs, the actions of the circulating
FGFs require the presence of specific membrane-bound core-
ceptors, a-Klotho or b-Klotho, and the expression of these deter-
mines the tissue specificity for the individual FGFs. a-Klotho is
mainly expressed in the kidney, parathyroid gland, and choroid
plexus, whereas b-Klotho is abundant in the liver and in brown
andwhite adipose tissue. Although FGF19may bind and activate
FGFR4 also in the absence of Klothos, its receptor selectivity is
still influenced by their expression pattern. a-Klotho interacts
with FGFR1c and converts it into a specific FGF23 receptor
(Urakawa et al., 2006). The importance of a-Klotho is evident
from the fact that mice lacking functional expression of a-Klotho
have a similar phenotype as FGF23 null mice, despite having
exceptionally high levels of circulating FGF23 (Larsson et al.,
2003). FGFR4, together with b-Klotho, is probably the major
receptor for FGF15/19 under physiological conditions, and elim-
ination of either of these structures results in a phenotype with
enhanced bile acid production similar to that seen in FGF15-defi-
cient animals (Inagaki et al., 2005; Ito et al., 2005; Yu et al., 2000).
FGFR1 in conjunction with b-Klotho seems to be the major
receptor for FGF21. Uncertainties remain as to the details of
how the interaction of the various FGF/FGFR/Klothos influences
the signaling of individual circulating FGFs, and there may be
‘‘promiscuity’’ (and diminished dependence of Klotho) at supra-
physiological concentrations of ligand (Faul et al., 2011; Wu
et al., 2011a). Studies of the potential relevance of circulating
FGFRs or Klothos in metabolic regulation are just emerging
and will probably add further to the complexity of interaction.
What Concentrations of Circulating FGFs Are Relevant
for Receptor Interaction?
When target cells have been incubated with FGFs, considerably
higher concentrations than those present in the circulation are
generally used to elicit a response. Although this may relate to
inadequate availability of cofactors such as Klotho, it is notable
that concentrations of FGF19 of 5 ng/mL or higher are needed
to repress bile acid synthesis in human hepatocytes (Holt
et al., 2003). This represents levels >10-fold above those
observed in the circulation in humans, even postprandially or
after treatment with bile acids (Lundasen et al., 2006). Further,
exposure of FGF21 to levels >1 mg/mL is needed to detect
a metabolic response in cultured human adipocytes (Arner
et al., 2008) or myocyte tubules (Mashili et al., 2011). The
concentrations used in the latter experiments are thus severalCell Metabolism 16, December 5, 2012 ª2012 Elsevier Inc. 695
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observed in normal humans, even after pharmacological or die-
tary interventions. This is also the case when animals are treated
with recombinant proteins or when subject to overexpression of
FGF19 or FGF21 (see below).
These discrepancies between the measured serum levels
in vivo and the concentrations needed to obtain metabolic
actions are of some concern when trying to assess the possible
physiological relevance of variations in circulating FGFs in
humans. Further, at least for FGF23, both active and inactive
fragments can be seen in some conditions (Yamazaki et al.,
2002), and it may well be that the same is true for the other circu-
lating FGFs. If so, the apparent gap between measured concen-
trations and potentially active levels could be even more
pronounced. On the other hand, there may be higher levels of
FGFs in certain vascular beds, e.g., the portal circulation for
intestinally derived FGF19. In preliminary studies in humans
(our unpublished data), we have not found any evidence of that
so far, but this should be an important question for further
exploration.
Fibroblast Growth Factor 23
Circulating FGF23 as a Regulator of Mineral Metabolism
As the first member of the FGF19 gene family to be established
as a circulating one, FGF23 was identified in 2000 as the causa-
tive factor of autosomal dominant hypophosphatemic rickets
(ADHR Consortium, 2000) and as the pathogenic factor in
tumor-induced osteomalacia (TIO) (Shimada et al., 2001). These
disorders are characterized by hypophosphatemia due to
reduced renal reabsorption of phosphate, and inadequately
low-normal 1,25(OH)2D3 levels, suggesting a critical role of
FGF23 in the control of phosphate and vitamin D metabolism.
There is rather convincing evidence that FGF23 can be consid-
ered to act as a ‘‘hormone,’’ in that the circulating protein exerts
metabolic effects in target tissues. This emanates from studies
both in animal models and in human genetic and malignant
diseases (ADHR Consortium, 2000; Larsson et al., 2004;
Shimada et al., 2001, 2004; White et al., 2001). Transgenic over-
expression or administration of recombinant FGF23 protein in
rodents consistently leads to hypophosphataemia and reduced
1,25(OH)2D3 levels. FGF23 induces phosphaturia through
decreased expression and endocytosis of the sodium-depen-
dent phosphate cotransporters Npt2a and Npt2c in the kidney
proximal tubule. FGF23 directly suppresses renal 1a-hydroxy-
lase, leading to decreased conversion of 25-hydroxyvitamin D3
(25[OH]D3) to its active metabolite 1,25(OH)2D3. FGF23 also
reduces both 25(OH)D3 and 1,25(OH)2D3 levels due to stimula-
tion of the 24-hydroxylase, an enzyme that has the capacity to
inactivate these metabolites. Finally, it has been shown that
FGF23 acts directly upon the parathyroid, inhibiting PTH gene
transcription and protein secretion (Ben-Dov et al., 2007; Krajis-
nik et al., 2007).
In addition to ADHR and TIO, increased levels of FGF23
are present in many skeletal disorders such as X-linked hypo-
phosphatemic rickets, autosomal recessive hypophosphatemic
rickets, fibrous dysplasia/McCune-Albright syndrome, linear
sebacceous nevus syndrome, osteoglophonic dysplasia and
Jansen’s metaphyseal chondroplasia (Brown et al., 2009; White
et al., 2006). On the other hand, inactivating mutations in the696 Cell Metabolism 16, December 5, 2012 ª2012 Elsevier Inc.FGF23 gene cause familial tumoral calcinosis, which is charac-
terized by a phenotype ‘‘opposite’’ to ADHR and TIO, including
hyperphosphatemia, elevated 1,25(OH)2D3 levels, and soft
tissue and/or vascular calcification (Benet-Pages et al., 2005;
Larsson et al., 2005). A similar pattern is seen with mutations in
the GALNT3 gene, which is responsible for posttranslational
O-glycosylation of FGF23. Such patients have low or undetect-
able levels of biologically intact FGF23 but high levels of inactive
C-terminal fragments, due to aberrant FGF23 processing.
The regulation of FGF23 synthesis and secretion from bone is
only partially understood. An important aspect of FGF23 regula-
tion is the autocrine, intracellular processing of FGF23 prior to
its entrance into the blood stream. FGF23-producing bone cells
are able to ‘‘sense’’ the required extracellular concentration of
bioactive FGF23 and can rapidly modify the relationship
between secreted intact and C-terminal fragments. Pathologi-
cally altered processing of FGF23 is observed in hereditary
disorders such as ADHR and TC but could also be part of a phys-
iological adaptive response during conditions such as anemia.
1,25(OH)2D3 is the most rapid and potent stimulator of FGF23,
whereas dietary phosphate intake, chronic hyperphosphatemia,
PTH, and most likely calcium also stimulate FGF23 release
(Figure 1). There are also data linking FGF23 to energy metabo-
lism, since leptin increases FGF23 (Tsuji et al., 2010). Similarly,
estrogens serve as a positive regulator of FGF23 (Carrillo-Lopez
et al., 2009). Importantly, vitamin D treatment increases FGF23
levels within 3–4 hr after intravenous administration, whereas
dietary phosphate intake elicits more subtle effects that are
observed within days after continuous loading (Ferrari et al.,
2005). It has been argued that dietary phosphate loading may
be more important than serum phosphate levels in terms of
FGF23 regulation. However, based on a large number of obser-
vational and interventional studies, especially in patients with
chronic kidney disease (CKD; see below), it seems clear that
circulating phosphate level is a critical determinant of FGF23.
Role of FGF23 in Chronic Kidney Disease
FGF23 plays an important role in CKD, in which its levels can
be elevated 1,000-fold or more. Although FGF23 presumably
undergoes renal clearance, there are few or no inactive
C-terminal fragments of FGF23 in the circulation of CKD patients
undergoing hemodialysis (Shimada et al., 2010), a finding also
supported by the very high correlation coefficient between
FGF23 measured with a C-terminal ELISA (detecting both
C-terminal and intact protein) and an intact ELISA (detecting
only the biologically active protein).
The reason for increased FGF23 in CKD remains to be
elucidated. It was initially considered to be a compensatory
mechanism to promote renal phosphate excretion and coun-
teract phosphate retention, a cardinal feature of CKD. However,
current data suggest that elevation of FGF23 is an early
biomarker of CKD, preceding other overt changes in mineral
metabolism, and an acute kidney injury rapidly (within hours)
stimulates the release of FGF23 from bone. It has been specu-
lated that the failing kidney releases a FGF23 stimulatory factor
or downregulates a tonic FGF23 inhibitor (Larsson, 2010).
Furthermore, the renal coreceptor a-Klotho is suppressed in
the very earliest stages of CKD, potentially causing FGF23
‘‘resistance’’ and a secondary rise in FGF23 (Hu et al., 2011;
Olauson et al., 2012). Regardless of mechanism, phosphate
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in CKD.
The consequence of high FGF23 levels in CKD is currently
under debate. Observational studies have shown that a higher
FGF23 level is independently associated with increased
mortality, CKD progression, and/or cardiovascular disease
across all strata of GFR and in renal transplant recipients (Gutier-
rez et al., 2008; Isakova et al., 2011; Wolf et al., 2011). In cross-
sectional studies, higher FGF23 is associated with multiple
cardiovascular risk factors such as arterial calcification, athero-
sclerosis, left ventricular hypertrophy, endothelial dysfunction,
arterial stiffness, the metabolic syndrome, hypertension, and
proteinuria (Gutierrez et al., 2009; Lundberg et al., 2012; Mirza
et al., 2009, 2011).
Thus, there is remarkable concordance in the evidence
favoring FGF23 as a marker for poor clinical outcome. Yet,
observational data cannot prove causality, and the question
remains whether FGF23 is merely a biomarker or directly toxic,
especially at the high concentrations observed in many CKD
patients. Very recent studies have shed some light on this
question. Some in vitro data suggest that FGF23 modulates
vascular properties, but additional work is needed to support
this conclusion. On the other hand, it has been postulated that
FGF23 could have ‘‘off-target’’ (i.e., Klotho-independent) effects
by promiscuous activation of one or several FGF receptors in
other organs than kidneys and parathyroid glands. This concept
recently gained some support from a study in mice showing
that systemic or intracardiac injections of FGF23 activate the
calcineurin-NFAT pathway in cardiomyocytes in a Klotho-
independent fashion (Faul et al., 2011). FGF23 has direct effects
on the myocardium, inducing left ventricular cardiac hyper-
trophy. Collectively, FGF23 is thus a potentially useful clinical
biomarker in CKD andmay be directly involved in the pathophys-
iology of cardiovascular disease. Further studies are warranted
to fully address this important issue.
Does FGF23 Have Other Metabolic Effects?
An intriguing question is whether FGF23 exerts metabolic effects
beyond mineral metabolism. This hypothesis is plausible based
on its structural similarity with FGF19 and FGF21, and its associ-
ation to cardiovascular disease. Cross-sectional data in two
community-based cohorts demonstrate that higher FGF23
correlates to increased fat mass, larger waist circumference,
and an adverse lipid profile, including low HDL cholesterol and
apoA-I, and higher triglycerides (Mirza et al., 2011). FGF23
knockout mice suffer from a disrupted glucose homeostasis
and fat metabolism, including hypoglycemia, increased periph-
eral insulin sensitivity, and reduced fat mass. However, these
abnormalities are largely reversed upon simultaneous ablation
of the VDR (Streicher et al., 2012), suggesting that the observed
metabolic effects are mediated by changes in vitamin D metab-
olism rather than being a primary effect of FGF23. In sum, there
are no current data supporting a direct role of FGF23 in glucose
and lipid metabolism, although this hypothesis has not been fully
explored in experimental studies.
Since FGF23 acts in a hormone-like manner, it is relevant to
search for ways to modulate its concentration, and to explore
its potential regulation through means such as diet, lifestyle,
and pharmacological treatment. Dietary phosphate restriction
has a minor impact on circulating FGF23 in individuals withnormal kidney function, whereas dietary phosphate loading
increases FGF23 (Ferrari et al., 2005). Observational data
suggest that higher phosphate intake is associated with higher
FGF23 (Gutierrez et al., 2011). Phosphate-binding therapy and
calcimimetics (allosteric agonists of the calcium-sensing
receptor that reduce PTH and secondarily lower calcium and
phosphate due to a reduction of bone turnover rate) efficiently
reduce FGF23 levels in moderate CKD and in dialysis patients
(Oliveira et al., 2010; Wetmore et al., 2010). In contrast, most
activators of the VDR appear to stimulate FGF23 expression
(Hansen et al., 2011).
Fibroblast Growth Factor 19
Circulating FGF19 Reflects Ileal Exposure to Bile Acids
The presence of circulating FGF19 in normal humans was first
described in 2006 (Lundasen et al., 2006). Its concentration
has a diurnal variation elicited by food intake and is closely
related to postprandial serum bile acid levels, in agreement
with the concept that synthesis and secretion of FGF19 take
place mainly in the terminal ileum through activation of the
nuclear receptor FXR by absorbed bile acids. Upon withdrawal
of food intake, serum levels of both bile acids and FGF19 remain
unchanged. Treatment with a bile acid-binding resin such as
cholestyramine strongly reduces fasting FGF19 levels, whereas
treatment with the primary bile acid, chenodeoxycholic acid,
increases FGF19 by 2.5-fold (Figure 3) (Lundasen et al., 2006).
The role of transintestinal bile acid flux in the regulation of circu-
lating FGF19 is also obvious from the fact that patients with bile
acid malabsorption—either secondary to resection or irradiation
damage or in its idiopathic form—have reduced levels of FGF19
in the overnight fasting state (Pattni et al., 2012; Walters et al.,
2009). Recent studies (B. Sjo¨berg, S. Straniero, B.A., and M.R.,
unpublished data) show that it takes at least 6 days after
cessation of resin therapy until the reduced FGF19 levels are
normalized, indicating that adaptive changes are induced for
a considerable time.
In mice, FGF15 mRNA expression in the terminal ileum is
clearly regulated by intestinal bile acids or FXR agonists, and
studies in total or intestine-specific FXR knockout animals
have elegantly confirmed this concept (Kim et al., 2007; Stroeve
et al., 2010). While cultured intestinal cells secrete FGF15 in
response to incubation with bile acids or FXR agonists (Sinha
et al., 2008), it has so far not been possible to detect directly
the FGF15 protein in blood using antibodies or protein analysis
(Montagnani et al., 2011). There is some indication that intestinal
FGF15 or FGF19 can suppress the expression of the active ileal
bile acid transporter (IBAT, also known as ASBT or Slc10a2)
(Sinha et al., 2008), but whether this occurs in vivo in humans
is still not known.
Does Circulating FGF19 Regulate Bile Acid Synthesis?
In normal humans sampled after overnight fast, there is an
inverse but weak relationship between serum FGF19 and bile
acid synthesis (Figure 3) (Galman et al., 2011; Pattni et al.,
2012). The profound lowering of FGF19 induced by cholestyr-
amine treatment is associated with an up to 18-fold stimulation
of bile acid synthesis, whereas the 2.5-fold increase in FGF19
following chenodeoxycholic acid treatment is associated with
30% reduction of bile acid production (Figure 3) (Lundasen
et al., 2006). Analysis of the respective circadian changes inCell Metabolism 16, December 5, 2012 ª2012 Elsevier Inc. 697
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Figure 3. Relationship between Serum FGF19 and Bile Acid
Synthesis
Data from a study in which levels of FGF19 are related to bile acid production
monitored by assay of the serum marker 7a-OH-4-cholestene-3-one (C4c) in
435 healthy subjects (Galman et al., 2011). The range of values for subjects
treated with the bile acid-binding resin, cholestyramine (n = 4), or the bile acid,
chenodeoxycholic acid (n = 6), is indicated by red and blue boxes, respectively
(Lundasen et al., 2006).
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temporal patterns consistent with a scenario where FGF19 is
secreted in response to bile acid transintestinal flux that in turn
suppresses bile acid synthesis in the liver (Lundasen et al.,
2006). However, all these findings are correlative, and it is still
unclear to what extent circulating FGF19 directly determines
bile acid synthesis, and how many other mechanisms in the liver
governed by portal venous bile acids are involved. From the
correlation between FGF19 levels and bile acid synthesis
(Figure 3), it appears that lowering of FGF19 results in much
more pronounced changes in bile acid synthesis than does
increasing FGF19 (Figure 3). A similar situation is seen in subjects
with bile acid malabsorption (Pattni et al., 2012).
Although the human data are compatible with, but do not
prove, the concept that FGF19 signaling is involved in the normal
feedback control of bile acid synthesis, most of the current
strong evidence for this model emanates from experiments in
genetically modified animals. Thus, bile acid synthesis is
increased in mice deficient in either FGF15, b-klotho, or FGFR4
(Inagaki et al., 2005; Ito et al., 2005; Yu et al., 2000), and this
increase can be reverted by overexpression of FGF15 or
FGF19, or by infusion of these proteins. It is of some concern698 Cell Metabolism 16, December 5, 2012 ª2012 Elsevier Inc.that the doses used to suppress bile acid synthesis in these
reports are generally as high as 0.4–1 mg/kg/day (Kir et al.,
2011a; Wu et al., 2011a). Direct measurements of circulating
FGF19 by ELISA in mice infused with 1 ng/hr of human
FGF19 demonstrated average levels of 26 ng/mL (Wu et al.,
2011a). This corresponds to levels >80 times higher than those
measured in humans treated with chenodeoxycholic acid
(Figure 3).
In mice lacking intestinal FXR, it has been shown that FGF15
gene expression is strongly reduced (Kim et al., 2007; Stroeve
et al., 2010). Interestingly, those animals respond just as well
as wild-type mice to resin or bile acid feeding, and their diurnal
rhythm of bile acid synthesis remains, although at a slightly
reduced level (Stroeve et al., 2010). These observations are diffi-
cult to harmonize with the thinking that plasma levels of FGF15
(which have still not been possible to detect) should be a major
regulator of bile acid synthesis. In a very recent study, Kong
et al. were able to obtain suppression of CYP7A1 by injection
of 10 mg/kg of recombinant FGF15 (Kong et al., 2012). By using
a number of tissue-specific knockouts they concluded that, in
mice, FGF15 signaling in the liver was more important than
(bile-acid-induced) hepatic FXR signaling in the regulation of
CYP7A1 expression. Thus, although the presence of intact
FGF15 signaling is obviously essential for the maintenance of
normal enterohepatic feedback regulation of bile acid synthesis
in mice, its relative contribution is still not fully established.
Studies of the phenotype in heterozygous (+/) knockout
animals could be relevant to get further insight into this question.
In humans, while circulating FGF19 levels are largely regulated
by the transintestinal flux of bile acids, the evidence that this
circulating FGF19 exerts direct effects on hepatic bile acid
synthesis is still incomplete. The interactions between bile acids,
FXR, and FGF19 both in the intestine and in the liver make it very
difficult to perform convincing experiments in man. The critical
testing of this hypothesis would require studies where FGF19
is infused into the circulation. Unfortunately, the observations
of cell-proliferative effects of FGF19 in animal studies (Nicholes
et al., 2002) preclude such experiments. The recent report that
high doses of anti-FGF19 antibodies given to cynomolgus
monkeys increased bile acid synthesis (Pai et al., 2012) may
point to an interesting primate model for future studies.
For FGF23, the initial observations in patients with very high
circulating levels due to genetic or tumor disease were of great
importance for understanding its role in human physiology. It is
tempting to speculate that similar situations may exist for
FGF19. Actively screening for grossly elevated FGF19 levels in
sera from patients with endocrine gut tumors could be a way
to identify such individuals. The subsequent elucidation of their
metabolic phenotype, including bile acid metabolism, would be
of great interest. Also, screening of patients with bile acid
diarrhea for mutations in FGF19 and its related genes may prove
to be valuable.
Is Circulating FGF19 Involved in Other Aspects of
Hepatobiliary Disease?
Mice deficient in FGF15, FGFR4, or b-klotho all have small
gallbladders, and it has been proposed that FGF15 released
from the small intestine by absorbed bile acids would normally
elicit gallbladder filling after a meal (Choi et al., 2006). However,
those results were obtained after intravenous injection of
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a calculated initial plasma peak value of FGF19 being 25,000
times higher (10 mg/ml) than that observed in human plasma after
a meal or after bile acid feeding (400 pg/ml; Figure 3). Whether
such a gallbladder response is present in humans is not known,
and this should be an important area for future studies.
Recent studies in humans have described that the gallbladder,
and biliary cholangiocytes, may be a site of FGF19 synthesis,
suggesting that the intestine may be exposed to significant
amounts of FGF19 in the bile (Zweers et al., 2012). However,
despite having twice normal synthesis rates of bile acids,
cholecystectomized subjects as a group have normal serum
levels of FGF19 (Galman et al., 2011). This observation does
not support the idea that synthesis of FGF19 in the gallbladder
contributes to circulating FGF19 levels in an important way.
Further studies are needed to explore the potential role of biliary
FGF19 in humans.
Another interesting report states that FGF19 mRNA can be
synthesized in human liver in situations of biliary obstruction
(Schaap et al., 2009). This would be in line with the original
studies by Holt et al. (Holt et al., 2003) and Song et al. (Song
et al., 2009), in which FGF19 mRNA levels were increased in
human hepatocytes when incubated with human bile acids at
concentrations compatible with those seen in cholestatic serum.
We have recently confirmed and expanded these observations,
with 10-fold elevations of serum FGF19 in subjects with biliary
obstruction, concomitant with a modest 33% reduction of bile
acid synthesis (Rudling et al., 2012). These results are in sharp
contrast to those previously reported for mice (Inagaki et al.,
2005), where ligation of the bile duct results in reduced intestinal
expression of FGF15, no change in hepatic FGF15 mRNA, and
a concomitant increase in bile acid synthesis. The latter findings
have been taken as evidence that lack of intestinal FGF19
derepresses bile acid synthesis in this species. There could be
other explanations for this paradoxical response, however.
Thus, following ligation of the bile duct in rodents, FXR-signaling
bile acids—such as deoxycholic acid—are strongly reduced,
while muricholic acids increase markedly (Zhang et al., 2012).
The latter mouse bile acids are in fact FXR antagonists (Islam
et al., 2012), and when given to rodents they actually stimulate
bile acid synthesis (Wang and Tazuma, 2002). Therefore,
a decreased FXR signaling due to the reduction of FXR agonists
combined with an increased level of FXR antagonists is a plau-
sible alternative explanation to the metabolic response in bile
duct-ligated mice. Whether this species difference in bile acid
composition may also play a role in explaining the pronounced
quantitative difference in basal bile acid production between
mice and men (Galman et al., 2003) remains to be elucidated.
Is Circulating FGF19 a Physiological Modulator of
Carbohydrate and Lipid Metabolism?
In early studies, exciting effects on carbohydrate and lipid
metabolism were seen in mouse models of obesity and diabetes
following overexpression of FGF19 or treatment with recom-
binant FGF19 (Fu et al., 2004; Tomlinson et al., 2002). The further
therapeutic developments were, however, hampered by indica-
tions of a liver proliferative response (Nicholes et al., 2002). Kir
et al. have recently carefully defined the signaling pathways acti-
vated in response to administration of FGF19 in mice (Kir et al.,
2011a; Potthoff et al., 2011) and postulated a model whereinFGF19 can be seen as a postprandial, incretin-like enterokine
regulating hepatic protein and glycogen synthesis and gluco-
genesis (Kir et al., 2011b). Also, analogs of FGF19 have been
developed where the risk of initiating proliferation should be
minimized (Wu et al., 2011a). However, it has to be realized
that the doses employed in these experiments (0.2–1 mg/kg/
day) correspond to grossly supraphysiological levels of the
circulating protein in humans, as described above.
Whether abnormalities in FGF19 may underlie manifestations
of metabolic disease in humans is not known presently. It is
well known that manipulations of the enterohepatic circulation
of bile acids can influence plasma triglyceride turnover and
concentration. For example, cholestyramine treatment in-
creases, and chenodeoxycholic acid decreases, triglyceride
synthesis (Angelin et al., 1978). The corresponding changes
induced in circulating FGF19 levels (Figure 3) would be compat-
ible with a role of this protein in the regulation of hepatic triglyc-
eride production. However, while bile acid overproduction is
a feature of some individuals with genetic hypertriglyceridemia
(Angelin et al., 1987), no obvious relation to FGF19 has been
found in this condition so far (Galman et al., 2011). The hypoth-
esis that low FGF19 would increase the risk for subsequent
development of type 2 diabetes has recently been refuted in
one 10 year prospective study (Angelin et al., 2010), but this
needs to be confirmed in additional studies.
Fibroblast Growth Factor 21
Is Circulating FGF21 a Physiological Metabolic
Regulator?
Regarding its possible role as a circulating metabolic regulator,
the situation for FGF21 is even more complex than for FGF19,
and there are a number of species differences making it difficult
to evaluate its function in humans. Like FGF19, soon after its
cloning, FGF21 was tested for its potential biological effects in
tissue culture screening and animal models (Kharitonenkov
et al., 2005). It is clear that when infused into animals at high
doses (0.1–1 mg/kg/day), or following gene transfer, FGF21
exerts positive metabolic effects, including overweight reduc-
tion, lowering of elevated blood glucose and triglycerides, and
increased insulin sensitivity (Kharitonenkov et al., 2005, 2007;
Xu et al., 2009). While these effects are robust in models of over-
weight and diabetes, they are generally less evident or even
absent in normal animals. Hepatic expression of FGF21 was
initially shown to be regulated by PPARa (Badman et al., 2007;
Inagaki et al., 2007; Lundasen et al., 2007). Since the hepatic
expression of FGF21 mRNA is strongly induced in mice during
fasting or when fed a ketogenic diet (Badman et al., 2007; Inagaki
et al., 2007), FGF21 was initially described as a ‘‘master switch’’
for the metabolic response to fasting (Reitman, 2007). Of note,
the metabolic phenotype in mice deficient in FGF21 is not very
prominent, with no development of hyperglycemia or insulin
resistance and differing reports regarding adaptation to ketosis
(Badman et al., 2009; Hotta et al., 2009).
A number of elegant studies have been performed in mice,
rats, and monkeys to pinpoint the possible molecular mecha-
nisms of circulating FGF21 in metabolic regulation (Fisher
et al., 2010, 2011; Kharitonenkov et al., 2005, 2007; Potthoff
et al., 2009). Potential target tissues include liver, white and
brown adipose tissue, pancreas, and the brain. A commonCell Metabolism 16, December 5, 2012 ª2012 Elsevier Inc. 699
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activation of signaling pathways, both in the liver and in other
organs. For example, in studies utilizing the technique of direct
perfusion of the liver (Fisher et al., 2011), serum levels of
FGF21 measured after passing through the liver were 9,000–
38,000 pg/mL, obviously vastly surpassing the normal range.
FGF21 was first reported to be present as a circulating protein
in humans in 2008 (Chen et al., 2008; Galman et al., 2008; Zhang
et al., 2008). The levels of FGF21 are generally higher than those
of FGF19, and the interindividual variation is wider (Figure 2). In
contrast to FGF19, there is no variation that can be related to
food intake, and there are no effects of induced perturbations
of the enterohepatic circulation (Galman et al., 2008). In contrast
to the pronounced stimulation in mice, it is surprising that, in
humans, fasting for up to 72 hr or treatment with a ketogenic
diet, two situations with pronounced ketosis, do not influence
circulating FGF21 levels (Christodoulides et al., 2009; Dushay
et al., 2010; Galman et al., 2008). Even after starvation (7 days
fasting), FGF21 levels are only modestly elevated. Treatment
with a PPARa activator results in 30% increased serum
FGF21 levels (Christodoulides et al., 2009; Galman et al.,
2007), again a very modest change. It is of interest to note
that, in humans, none of these perturbations increase serum
FGF21 to levels that surpass those seen as part of the normal
interindividual variation (Figure 2), again casting some doubt as
to whether changes of this magnitude can be of physiological
relevance.
FGF21 Is Increased in Conditions of Obesity, Insulin
Resistance, and Fatty Liver
Based on the robust therapeutic effects of FGF21 in animals, it
was originally believed that situations of overweight and dia-
betes would be associated with reduced expression of FGF21.
Therefore, it was surprising when many studies demonstrated
that FGF21 levels are generally increased in subjects with
abdominal obesity, insulin resistance, and type 2 diabetes, as
well as in those with fatty liver or hypertriglyceridemia (Chavez
et al., 2009; Dushay et al., 2010; Galman et al., 2007; Li et al.,
2009; Zhang et al., 2008). Frequently, but not invariably, there
is also a correlation between high FGF21 levels and disease
severity. Together with the finding of 12-fold increases in
hepatic FGF21 mRNA levels in ob/ob mice, (Fisher et al., 2010;
Lundasen et al., 2007), these observations led to the proposal
that there could be ‘‘FGF21 resistance’’ in these situations, in
some similarity with the hyperleptinemia and hyperinsulinemia
frequently seen. A detailed study of insulin-resistant mice did
not show overt FGF21 resistance, however (Hale et al., 2012).
In general, the response in FGF21 to metabolic load appears
to be more drastic in mice than in humans, and there are
a number of clear species differences. This is also true for the
influence of several hormones. For example, thyroxin stimulates
hepatic mRNA expression and increases plasma levels of FGF21
in mice (Adams et al., 2010), whereas this is not observed in
humans (Y. Bonde, O. Breuer, D. Lutjohann, S. Sjo¨berg, B.A.,
and M.R., unpublished data).
While the morning concentration of FGF21 after overnight fast
is rather stable over long periods of time in a given individual
(Angelin et al., 2010), there is a diurnal variation with lowered
levels during the afternoon (Galman et al., 2007; Lee et al.,
2012; Yu et al., 2011). This may be related to variation in FFA700 Cell Metabolism 16, December 5, 2012 ª2012 Elsevier Inc.concentration, but more information is needed to establish the
possible role of adipose lipolysis for FGF21 secretion in humans,
including the possible role of paracrine or autocrine effects within
adipose tissue.
Why Are Such Large Doses of FGF21 Needed to Achieve
Metabolic Effects In Vivo?
One reason that large doses of FGF21 (and FGF19, for that
matter) are needed to elicit clear metabolic responses in
various target tissues could be that this is necessary to reach
local concentrations that will exert a ‘‘paracrine’’ or even an
‘‘autocrine’’ effect. Such a possibility would not be in line with
the concept that FGF21 acts as a hormone, but it would not
preclude an important role for the FGF21 signaling pathway in
the organ, nor the potential usefulness of developing therapies
based on these properties.
Another, quite exciting, possibility is that the effect of system-
ically administered FGF21 (and maybe FGF19) is dependent on
passage across the blood-brain barrier. It has been shown that
a substantial fraction (0.5%) of intravenously administered
FGF21 is recovered in the central nervous system in the rat
(Hsuchou et al., 2007), and that FGFR1s are expressed in the
ventrolateral hypothalamic nucleus. This represents an impor-
tant location for a number of efferent stimuli regulating appetite,
thermogenesis, and metabolic rate. In a recent study of high-fat-
fed rats, the administration of 0.4 mg/day of human FGF21 into
the lateral cerebral ventricle resulted in increased energy expen-
diture and enhanced insulin sensitivity, but there was no change
in body weight, probably due to increased food intake (Sarruf
et al., 2010). Following intraventricular administration there
was no measurable increase in peripheral circulating human
FGF21, however. It is also of interest to note that Fu et al. already
in 2004 reported an increased metabolic rate when mice were
given 0.5 mg/day of FGF19 into the lateral ventricle, indicating
that similar mechanisms may operate also for this protein (Fu
et al., 2004). The information on humans is very limited, but
Tan et al. have recently described that FGF21 can be measured
in cerebrospinal fluid (Tan et al., 2011). Further exploration into
whether, and if so how, FGF21 and FGF19 may exert some of
their peripheral metabolic effects through action on the central
nervous level should be an important field for future research.
Is Circulating FGF21 an Indicator of Metabolic
Imbalance?
As mentioned, clinical conditions such as abdominal adiposity,
hepatic steatosis, insulin resistance, hypertriglyceridemia, and
type 2 diabetes are frequently associated with increased levels
of serum FGF21 (Chavez et al., 2009; Dushay et al., 2010;
Galman et al., 2008; Li et al., 2009; Zhang et al., 2008). In
some studies, elevated FGF21 levels correlate with the degree
of metabolic disturbance, and are reduced in response to
correcting interventions. It is generally assumed that these
changes reflect the hepatic production of FGF21, but that has
not been fully established. Increased expression in adipose
tissue, muscle, or pancreas may also, at least partly, be respon-
sible. Obviously, one interpretation of these findings is that they
represent a ‘‘protective’’ response to a ‘‘metabolic overload’’
that would lead to modulation of glucose and lipid metabolism
in tissues such as fat andmuscle. Considering the low circulating
levels in relation both to the normal variation in healthy subjects
and to the levels needed to induce metabolic responses, it
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any major modification of metabolism in their own virtue,
however. Instead, the increased levels of FGF21 in such situa-
tions may reflect a ‘‘spill-over’’ from cells subject to ‘‘metabolic
stress’’ that could have been induced by, e.g., disturbed
membrane stability in the endoplasmic reticulum (Fu et al.,
2012). The recent observation that FGF21 levels are higher,
and related to disease activity, in patients with mitochondrial
disease and muscle manifestations (Suomalainen et al., 2011)
would be compatible with this view. It is also interesting to note
that we have observed that, although subjects with impaired
glucose tolerance or diabetes type 2 have higher FGF21 levels
than matched controls, this difference between the groups was
already manifested 10 years before diagnosis, when all individ-
uals had a documented normal glucose tolerance (Angelin
et al., 2010). Thus, independent of all other risk factors, elevated
FGF21 is associated with an 2-fold increased risk for subse-
quent diabetes, a finding recently also shown in a smaller number
of subjects followed over a shorter period of time (Chen et al.,
2011). On the other hand, reduced hepatic steatosis (assessed
by magnetic resonance imaging) and serum transaminase levels
in response to dietary intervention with polyunsaturated fat are
not paralleled by a decreased level of FGF21 (Bjermo et al.,
2012). These observations indicate that in some but probably
not all situations, serum FGF21 may be a marker of metabolic
imbalance. Expanded and more detailed studies will be impor-
tant to evaluate if this could be of use in clinical diagnosis.
Is There a Role for FGF21 in the Treatment of Human
Metabolic Disease?
From the first report on very favorable results of treatment with
FGF21 in animal models (Kharitonenkov et al., 2005), there has
been a large interest in developing therapies based on the pleoi-
tropic effects of FGF21 on carbohydrate and lipid metabolism.
While high-dose treatments with FGF21 and FGF19 have
comparable effects on energy homeostasis in insulin-resistant
mice, there is a clear difference in that FGF19, but not FGF21,
stimulates cell proliferation in the liver (Adams et al., 2012).
Interesting results, presumably reflecting paracrine actions of
FGF21, have also been reported for the use of this protein for
protection in animal models of pancreatitis and sepsis (Long
and Kharitonenkov, 2011), although the relevance of such thera-
pies in humans is not clear at the moment.
There is still very limited information in the public sector
regarding therapeutic trials of FGF21 in humans. The short
half-life of the circulating protein probably makes it difficult to
maintain levels high enough to achieve desired effects, and
much effort is made to create highly active molecules with
prolonged retention in the circulation (Veniant et al., 2012). Other
ways to activate the FGFRs may be more successful, and one
interesting approach that has been taken is to engineer anti-
bodies that elicit a prolonged activation of FGFRs (Wu et al.,
2011b). Considering the multitude of effects seen during high-
dose treatment in animals, a great amount of work regarding
safety issues will obviously be necessary before such drugs
could eventually enter clinical practice.
Concluding Remarks
In the continuous struggle with testing hypothetical models of
metabolic regulation, the words of Albert Einstein should alwaysbe considered: ‘‘Everything should be made as simple as
possible—but not simpler.’’ The circulating FGFs have emerged
as an exciting new group of metabolic companions, and the
study of their physiology, pathophysiology, and potential thera-
peutic roles has resulted in a number of working hypotheses,
generally based on the concept that they may act as regulatory
molecules similar to many of the classical hormones. When re-
viewing the current thinking, there are three aspects that should
be given particular consideration. First, there are a number of
clear species differences between mice and men regarding
metabolic pathways, which may explain some of the discrep-
ancies that seem to exist. Second, it is important to remember
that the fact that the presence of a regulatory structure is critical
for a function does not immediately translate to it being an impor-
tant regulator in its own virtue. Third, the fact that effects can be
seen in response to supraphysiological levels of a compound
does not always imply that this mechanism is at work under
normal conditions.
In this review, we have tried to point to some of the remaining
questions in this expansive scientific area, with special emphasis
on the possible relevance of circulating FGFs as hormone-like
regulators of metabolism in humans. At this particular moment,
we would propose (1) that the role of circulating FGF23 as
a pivotal regulator of phosphate and vitamin D metabolism is
rather well established; (2) that, although the demand for an
intact FGF19 signaling pathway is of critical importance formain-
taining normal feedback regulation of bile acid synthesis, it is still
not clear how and to which extent circulating FGF19 mediates
this regulation; (3) that the physiological role of circulating
FGF21 in the regulation of lipid and carbohydrate metabolism
still remains to be clarified; (4) that, despite the uncertainty of
their physiological roles, further exploration of treatment modal-
ities mimicking high doses of FGF21, and possibly FGF19,
should be of great interest; and (5) that measurements of circu-
lating FGFs may become useful as markers of metabolic activity
or risk in certain conditions. Future work, integrating as well as
segregating models of animal and human metabolism, should
give important insights as well as novel possibilities for refined
diagnosis and treatment in important human diseases.ACKNOWLEDGMENTS
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